
Hiram S Cody

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4955231/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. Journal of Clinical Oncology, 2005, 23, 7703-7720.	1.6	1,674
2	A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Annals of Surgical Oncology, 2003, 10, 1140-1151.	1.5	747
3	Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2014, 32, 1365-1383.	1.6	713
4	The Risk of Axillary Relapse After Sentinel Lymph Node Biopsy for Breast Cancer Is Comparable With That of Axillary Lymph Node Dissection. Annals of Surgery, 2004, 240, 462-471.	4.2	370
5	Lessons Learned From 500 Cases of Lymphatic Mapping for Breast Cancer. Annals of Surgery, 1999, 229, 528-535.	4.2	339
6	Sentinel Lymph Node Biopsy: Is It Indicated in Patients With High-Risk Ductal Carcinoma-In-Situ and Ductal Carcinoma-In-Situ With Microinvasion?. Annals of Surgical Oncology, 2000, 7, 636-642.	1.5	304
7	Preoperative Ultrasound-Guided Needle Biopsy of Axillary Nodes in Invasive Breast Cancer. Annals of Surgery, 2011, 254, 243-251.	4.2	290
8	Doctor, What Are My Chances of Having a Positive Sentinel Node? A Validated Nomogram for Risk Estimation. Journal of Clinical Oncology, 2007, 25, 3670-3679.	1.6	283
9	Complementarity of Blue Dye and Isotope in Sentinel Node Localization for Breast Cancer: Univariate and Multivariate Analysis of 966 Procedures. Annals of Surgical Oncology, 2001, 8, 13-19.	1.5	251
10	Intradermal Radiocolloid and Intraparenchymal Blue Dye Injection Optimize Sentinel Node Identification in Breast Cancer Patients. Annals of Surgical Oncology, 1999, 6, 450-454.	1.5	233
11	How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Annals of Surgical Oncology, 2016, 23, 3467-3474.	1.5	232
12	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	196
13	Is Routine Intraoperative Frozen-Section Examination of Sentinel Lymph Nodes in Breast Cancer Worthwhile?. Annals of Surgical Oncology, 2000, 7, 651-655.	1.5	182
14	Internal mammary node status: A major prognosticator in axillary node-negative breast cancer. Annals of Surgical Oncology, 1995, 2, 32-37.	1.5	170
15	Lymphovascular Invasion Enhances the Prediction of Non-Sentinel Node Metastases in Breast Cancer Patients With Positive Sentinel Nodes. Annals of Surgical Oncology, 2001, 8, 145-149.	1.5	160
16	A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer 1 1No competing interests declared Journal of the American College of Surgeons, 2001, 193, 473-478.	0.5	159
17	Reoperative Sentinel Lymph Node Biopsy: A New Frontier in the Management of Ipsilateral Breast Tumor Recurrence. Annals of Surgical Oncology, 2007, 14, 2209-2214.	1.5	142
18	Occult Axillary Node Metastases in Breast Cancer Are Prognostically Significant: Results in 368 Node-Negative Patients With 20-Year Follow-Up. Journal of Clinical Oncology, 2008, 26, 1803-1809.	1.6	140

#	Article	IF	CITATIONS
19	Credentialing for Breast Lymphatic Mapping: How Many Cases Are Enough?. Annals of Surgery, 1999, 229, 723.	4.2	135
20	Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?. Journal of the American College of Surgeons, 2005, 200, 10-14.	0.5	134
21	The Accuracy of Sentinel Lymph Node Biopsy in Multicentric and Multifocal Invasive Breast Cancers. Journal of the American College of Surgeons, 2003, 197, 529-535.	0.5	127
22	A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram. Annals of Surgery, 2007, 245, 462-468.	4.2	126
23	Contralateral Prophylactic MastectomyÂ(CPM) Consensus Statement from the American Society of Breast Surgeons: Data on CPM Outcomes and Risks. Annals of Surgical Oncology, 2016, 23, 3100-3105.	1.5	125
24	Hereditary breast cancer. Current Problems in Surgery, 2001, 38, 387-480.	1.1	124
25	Sensory morbidity after sentinel lymph node biopsy and axillary dissection: A prospective study of 233 women. Annals of Surgical Oncology, 2002, 9, 654-662.	1.5	122
26	Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study. Annals of Surgical Oncology, 2016, 23, 257-264.	1.5	121
27	Reoperative Sentinel Lymph Node Biopsy. Journal of the American College of Surgeons, 2002, 195, 167-172.	0.5	120
28	Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Annals of Surgical Oncology, 2015, 22, 3174-3183.	1.5	116
29	The breast cancer patient with multiple sentinel nodes: when to stop?1 1No competing interests declared Journal of the American College of Surgeons, 2001, 192, 692-697.	0.5	115
30	State-of-the-art approaches to sentinel node biopsy for breast cancer:. Surgical Oncology, 1999, 8, 85-91.	1.6	112
31	Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma. Cancer, 2004, 100, 929-934.	4.1	101
32	The Results of Frozen Section, Touch Preparation, and Cytological Smear Are Comparable for Intraoperative Examination of Sentinel Lymph Nodes: A Study in 133 Breast Cancer Patients. Annals of Surgical Oncology, 2005, 12, 173-180.	1.5	101
33	Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy. Annals of Surgical Oncology, 2014, 21, 22-27.	1.5	99
34	Isosulfan Blue Dye Reactions During Sentinel Lymph Node Mapping for Breast Cancer. Anesthesia and Analgesia, 2002, 95, 385-388.	2.2	94
35	Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery, 2001, 130, 432-438.	1.9	93
36	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	90

#	Article	IF	CITATIONS
37	Sentinel lymph node mapping in breast cancer. Breast Cancer, 1999, 6, 13-22.	2.9	89
38	Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered11No competing interests declared Journal of the American College of Surgeons, 1999, 188, 377-381.	0.5	89
39	Sentinel Lymph Node Biopsy Is Successful and Accurate in Male Breast Carcinoma. Journal of the American College of Surgeons, 2008, 206, 616-621.	0.5	87
40	Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making. Annals of Surgical Oncology, 2016, 23, 3106-3111.	1.5	86
41	Clinical aspects of sentinel node biopsy. Breast Cancer Research, 2001, 3, 104-8.	5.0	85
42	Comprehensive review of the management of internal mammary lymph node metastases in breast cancer 1 1No competing interests declared Journal of the American College of Surgeons, 2001, 193, 547-555.	0.5	84
43	Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer, 2001, 91, 319-323.	4.1	83
44	Influence of Frozen-Section Analysis of Sentinel Lymph Node and Lumpectomy Margin Status on Reoperation Rates in Patients Undergoing Breast-Conservation Therapy. Journal of the American College of Surgeons, 2008, 206, 76-82.	0.5	76
45	Sentinel lymphadenectomy accurately predicts nodal status in T2 breast cancer11No competing interests declared Journal of the American College of Surgeons, 2000, 191, 593-599.	0.5	72
46	Obesity influences outcome of sentinel lymph node biopsy in early-stage breast cancer. Journal of the American College of Surgeons, 2003, 197, 896-901.	0.5	71
47	Localization of the Sentinel Node in Breast Cancer: Identical Results With Same-Day and Day-Before Isotope Injection. Annals of Surgical Oncology, 2001, 8, 682-686.	1.5	70
48	Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients. Annals of Surgical Oncology, 2001, 8, 592-597.	1.5	67
49	A Prospective Analysis of the Effect of Blue-Dye Volume on Sentinel Lymph Node Mapping Success and Incidence of Allergic Reaction in Patients With Breast Cancer. Annals of Surgical Oncology, 2004, 11, 535-541.	1.5	67
50	Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event. JAMA Oncology, 2021, 7, 1851.	7.1	61
51	Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients. Cancer, 2008, 112, 2052-2059.	4.1	59
52	Reoperative Sentinel Lymph Node Biopsy after Previous Mastectomy. Journal of the American College of Surgeons, 2008, 207, 543-548.	0.5	58
53	Characteristics and Outcomes of Sentinel Node–Positive Breast Cancer Patients after Total Mastectomy without Axillary-Specific Treatment. Annals of Surgical Oncology, 2012, 19, 3762-3770.	1.5	56
54	Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events. Cancer, 2004, 101, 926-933.	4.1	52

#	Article	IF	CITATIONS
55	Sentinel Lymph Node Biopsy after Percutaneous Diagnosis of Nonpalpable Breast Cancer. Radiology, 1999, 211, 835-844.	7.3	49
56	A 10-Year Trend Analysis of Sentinel Lymph Node Frozen Section and Completion Axillary Dissection for Breast Cancer: Are These Procedures Becoming Obsolete?. Annals of Surgical Oncology, 2012, 19, 225-232.	1.5	49
57	One-step Surgery for Breast Cancer: Back to the Future?. World Journal of Surgery, 2007, 31, 1155-1156.	1.6	46
58	Sentinel Lymph Node Drainage in Multicentric Breast Cancers. Breast Journal, 2002, 8, 356-361.	1.0	43
59	Sentinel Lymph Node Biopsy for Breast Cancer: Does Anybody Not Need One?. Annals of Surgical Oncology, 2003, 10, 1131-1132.	1.5	42
60	Axillary Node Staging for Microinvasive Breast Cancer: Is It Justified?. Annals of Surgical Oncology, 2012, 19, 3416-3421.	1.5	42
61	Current surgical management of breast cancer. Current Opinion in Obstetrics and Gynecology, 2002, 14, 45-52.	2.0	41
62	Extent of Microinvasion in Ductal Carcinoma In Situ is not Associated with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2014, 21, 3330-3335.	1.5	37
63	Rotter's Node Metastases. Annals of Surgery, 1984, 199, 266-270.	4.2	36
64	Axillary management in breast cancer: What's new for 2012?. Breast, 2012, 21, 411-415.	2.2	34
65	Reexcision — The Other Breast Cancer Epidemic. New England Journal of Medicine, 2015, 373, 568-569.	27.0	33
66	ls the "10% Rule―Equally Valid for All Subsets of Sentinel-Node-Positive Breast Cancer Patients?. Annals of Surgical Oncology, 2008, 15, 2728-2733.	1.5	28
67	Factors Associated with Reoperation in Breast-Conserving Surgery for Cancer: A Prospective Study of American Society of Breast Surgeon Members. Annals of Surgical Oncology, 2019, 26, 3321-3336.	1.5	28
68	Does the Benefit of Sentinel Node Frozen Section Vary Between Patients With Invasive Duct, Invasive Lobular, and Favorable Histologic Subtypes of Breast Cancer?. Annals of Surgery, 2008, 247, 143-149.	4.2	27
69	Reoperative Sentinel Lymph Node Biopsy is Feasible for Locally Recurrent Breast Cancer, But is it Worthwhile?. Annals of Surgical Oncology, 2016, 23, 744-748.	1.5	27
70	Radiation field design and regional control in sentinel lymph nodeâ€positive breast cancer patients with omission of axillary dissection. Cancer, 2012, 118, 1994-2003.	4.1	25
71	Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 2016, 23, 3481-3486.	1.5	25
72	The impact of mammography in 1096 consecutive patients with breast cancer, 1979-1993. Equal value for patients younger and older than age 50 years. Cancer, 1995, 76, 1579-1584.	4.1	23

#	Article	IF	CITATIONS
73	Is It Really Duct Carcinoma In Situ?. Annals of Surgical Oncology, 2001, 8, 617-617.	1.5	23
74	Surgical management of the axilla: do intramammary nodes matter?. American Journal of Surgery, 2009, 198, 532-537.	1.8	23
75	Point: Sentinel Lymph Node Biopsy Is Indicated for Patients With DCIS. Journal of the National Comprehensive Cancer Network: JNCCN, 2003, 1, 199-206.	4.9	22
76	Number of lymph nodes removed in sentinel lymph nodeâ€negative breast cancer patients is significantly related to patient age and tumor size. Cancer, 2010, 116, 1987-1991.	4.1	21
77	Redefining prognosis in node-negative breast cancer: Can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy?. Annals of Surgical Oncology, 2004, 11, 227S-230S.	1.5	20
78	Can Sentinel Lymph Node Biopsy Be Omitted in Patients With Favorable Breast Cancer Histology?. Annals of Surgical Oncology, 2005, 12, 24-28.	1.5	20
79	Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients. Annals of Surgical Oncology, 2020, 27, 1617-1624.	1.5	20
80	Surgical approach to internal mammary lymph node biopsy1 1No competing interests declared Journal of the American College of Surgeons, 2001, 193, 709-713.	0.5	19
81	Comparison of Local Recurrence Risk Estimates After Breast-Conserving Surgery for DCIS: DCIS Nomogram Versus Refined Oncotype DX Breast DCIS Score. Annals of Surgical Oncology, 2019, 26, 3282-3288.	1.5	19
82	Percutaneous Biopsy and Sentinel Lymphadenectomy. American Journal of Roentgenology, 2001, 177, 887-891.	2.2	18
83	Management of the axilla in early stage breast cancer: Will sentinel node biopsy end the debate?. , 1999, 71, 137-139.		16
84	Sentinel lymph node biopsy for breast cancer: indications, contraindications, and new directions. Journal of Surgical Oncology, 2007, 95, 440-442.	1.7	14
85	Sentinel Lymph Node Biopsy for DCIS: Are We Approaching Consensus?. Annals of Surgical Oncology, 2007, 14, 2179-2181.	1.5	14
86	Predictors of Completion Axillary Lymph Node Dissection in Patients With Immunohistochemical Metastases to the Sentinel Lymph Node in Breast Cancer. Annals of Surgical Oncology, 2010, 17, 1063-1068.	1.5	14
87	Clinical Significance and Management of Extra-Axillary Sentinel Lymph Nodes: Worthwhile or Irrelevant?. Surgical Oncology Clinics of North America, 2010, 19, 507-517.	1.5	14
88	Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon. Annals of Surgical Oncology, 2016, 23, 2456-2461.	1.5	14
89	ls Sentinel Lymph Node Biopsy Required for a Core Biopsy Diagnosis of Ductal Carcinoma In Situ with Microinvasion?. Annals of Surgical Oncology, 2019, 26, 2738-2746.	1.5	13
90	The clinical impact and outcomes of immunohistochemistry-only metastasis in breast cancer. American Journal of Surgery, 2010, 200, 368-373.	1.8	12

#	Article	IF	CITATIONS
91	Missed micrometastatic disease in breast cancer. Seminars in Oncology, 2004, 31, 311-317.	2.2	11
92	Impact of an In Situ Component on Outcome After In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy. Annals of Surgical Oncology, 2018, 25, 154-163.	1.5	11
93	Predicting Nonsentinel Node Metastases in Sentinel Node-Positive Breast Cancer: What Have We Learned, Can We Do Better, and Do We Need To?. Annals of Surgical Oncology, 2008, 15, 2998-3002.	1.5	10
94	Salvage of locally recurrent breast cancer with repeat breast conservation using 45ÂGy hyperfractionated partial breast re-irradiation. Breast Cancer Research and Treatment, 2021, 188, 409-414.	2.5	9
95	Predictors of Completion Axillary Lymph Node Dissection in Patients with Positive Sentinel Lymph Nodes. Annals of Surgical Oncology, 2009, 16, 1952-1958.	1.5	8
96	Management of ipsilateral breast tumor recurrence following breast conservation surgery: a comparative study of re-conservation vs mastectomy. Breast Cancer Research and Treatment, 2021, 187, 105-112.	2.5	8
97	Does the Rapid Acceptance of ACOSOG Z0011 Compromise Selection of Systemic Therapy?. Annals of Surgical Oncology, 2012, 19, 3643-3645.	1.5	6
98	Intradermal Isotope Injection: A Highly Accurate Method of Lymphatic Mapping in Breast Carcinoma. Annals of Surgical Oncology, 2001, 8, 20-24.	1.5	6
99	Sentinel Node Biopsy After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Does Axillary Ultrasound Improve Performance?. Journal of Clinical Oncology, 2015, 33, 3375-3378.	1.6	5
100	Reoperative Sentinel Lymph Node Biopsy: Adding Nuance to the Management of Locally Recurrent Breast Cancer. Annals of Surgical Oncology, 2016, 23, 9012-9014.	1.5	5
101	Breast-Conservation Therapy. , 2005, , 41-55.		5
102	Axillary Dissection for Breast Cancer. Operative Techniques in General Surgery, 2006, 8, 66-80.	0.0	4
103	Postdischarge Nonsteroidal Anti-Inflammatory Drugs Are not Associated with Risk of Hematoma after Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 5507-5512.	1.5	4
104	Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer, 2001, 91, 319-323.	4.1	4
105	Lymphovascular Invasion Enhances the Prediction of Non-Sentinel Node Metastases in Breast Cancer Patients With Positive Sentinel Nodes. Annals of Surgical Oncology, 2001, 8, 145-149.	1.5	4
106	The sentinel node concept: A critique of the critique. Breast, 2006, 15, 571-574.	2.2	3
107	Presidential Address: "A Part of the Mainâ€: Annals of Surgical Oncology, 2015, 22, 3161-3167.	1.5	3
108	SLN biopsy for large and/or multicentric breast cancers: Should we worry?. European Journal of Surgical Oncology, 2011, 37, 386-387.	1.0	2

#	Article	IF	CITATIONS
109	Preoperative staging of the axilla in women with invasive breast cancer. Breast Cancer Management, 2012, 1, 65-72.	0.2	2
110	Nomograms can predict non-sentinel node status in sentinel node-positive breast cancer, but are they still relevant?. Surgical Oncology, 2012, 21, 57-58.	1.6	2
111	Sentinel node biopsy and neoadjuvant chemotherapy. Lancet Oncology, The, 2013, 14, 567-568.	10.7	2
112	Extending ACOSOG Z0011 to Encompass Mastectomy: What Happens Without RT?. Annals of Surgical Oncology, 2017, 24, 621-623.	1.5	2
113	Highest Isotope Count Does Not Predict Sentinel Node Positivity in All Breast Cancer Patients. Annals of Surgical Oncology, 2001, 8, 592-597.	1.5	2
114	Mammographic Screening: A Surgeon's Perspective. Breast Journal, 1997, 3, 26-31.	1.0	1
115	How do we evaluate sentinel nodes and interpret the findings?. Current Breast Cancer Reports, 2009, 1, 12-20.	1.0	1
116	ASO Author Reflections: Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ with Suspicion for Microinvasion on Core Needle Biopsy. Annals of Surgical Oncology, 2019, 26, 704-704.	1.5	1
117	Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2022, 29, 1737-1745.	1.5	1
118	ASO Visual Abstract: Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy With Multimodal Analgesia. Annals of Surgical Oncology, 2022, 29, 1748-1749.	1.5	1
119	E14. Changing concepts in breast cancer surgery. European Journal of Cancer, Supplement, 2004, 2, 30-31.	2.2	0
120	The sentinel node concept: A critique of the critique. Breast, 2006, 15, 687-690.	2.2	0
121	Radioguided Sentinel Lymph Node Mapping and Biopsy in Breast Cancer. , 2016, , 115-123.		0
122	Detection and Significance of Axillary Lymph Node Micrometastases. , 2018, , 631-636.e2.		0
123	ASO Visual Abstract: Post-Discharge Non-Steroidal Anti-Inflammatory Drugs Are Not Associated with Risk of Hematoma After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia. Annals of Surgical Oncology, 2021, 28, 635-636.	1.5	0
124	Detection and Significance of Axillary Lymph Node Micrometastases. , 2009, , 1007-1015.		0
125	Sentinel Lymph Node Biopsy Radiotracer Technique at Memorial Sloan-Kettering Cancer Center. , 2010, , 481-488.		0